Traders Buy Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was the recipient of unusually large options trading on Thursday. Stock traders bought 28,173 call options on the stock. This represents an increase of approximately 70% compared to the average volume of 16,565 call options.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock traded down $5.25 during mid-day trading on Thursday, reaching $9.56. 58,699,830 shares of the company traded hands, compared to its average volume of 15,705,564. Iovance Biotherapeutics has a 52-week low of $1.76 and a 52-week high of $15.37. The firm has a market capitalization of $4.33 billion, a price-to-earnings ratio of -13.10 and a beta of 0.76. The firm’s 50 day moving average price is $11.35 and its 200 day moving average price is $5.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $99.31 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The business’s revenue for the quarter was up 65.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) EPS. On average, sell-side analysts anticipate that Iovance Biotherapeutics will post -0.45 EPS for the current year.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with nonsquamous metastatic non-small-cell lung cancer in the Phase 2 IOV-LUN-202 study. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched group reached 59.1%. The company said the data support a planned supplemental biologics license application for lifileucel in 2027 and will begin the POSITIVITY biomarker-enriched study in November. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Earlier melanoma-related data also showed lifileucel activity in difficult-to-treat tumors, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, reinforcing the potential to expand Iovance’s TIL platform beyond its current melanoma use. Lifileucel Shows 50% Response Rate
• Positive Sentiment: Zacks upgraded IOVA from “hold” to “strong buy,” while unusually heavy call-option activity and expectations for an earnings beat signal continued bullish positioning among some traders. Zacks Research Rating
• Neutral Sentiment: The company’s webcast highlighted its lung-cancer results and broader precision-immuno-oncology strategy, giving investors additional details on the development pipeline. Iovance Webcast Announcement
• Negative Sentiment: The sharp selloff indicates that investors may have considered the overall 24.6% response rate less compelling than the stronger biomarker-selected results, particularly because the KRAS-mutant subgroup achieved only an 11.4% response rate. The program remains investigational, with a possible regulatory submission not expected until 2027. Iovance Lung Cancer Twist

Analyst Ratings Changes

IOVA has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Tuesday, September 29th. HC Wainwright boosted their price objective on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. UBS Group lifted their target price on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Thursday, August 20th. Finally, Robert W. Baird upped their price target on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.20.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Iovance Biotherapeutics in the 2nd quarter worth approximately $153,744,000. Palo Alto Investors LP bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at approximately $22,032,229. Bank of America Corp DE bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at approximately $20,773,000. Mirador Capital Partners LP raised its stake in Iovance Biotherapeutics by 1.4% during the third quarter. Mirador Capital Partners LP now owns 1,095,740 shares of the biotechnology company’s stock valued at $16,239,000 after buying an additional 15,452 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Iovance Biotherapeutics by 71.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company’s stock valued at $9,282,000 after buying an additional 1,106,592 shares during the last quarter. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.